NRG1 overexpression
|
Esophageal Squamous Cell Carcinoma
|
NRG1 overexpression
|
Esophageal Squamous Cell Carcinoma
|
AV-203 Sensitive: C3 – Early Trials
|
AV-203 Sensitive: C3 – Early Trials
|
NRG1 overexpression
|
NSCLC
|
NRG1 overexpression
|
NSCLC
|
U3-1287 Sensitive: C3 – Early Trials
|
U3-1287 Sensitive: C3 – Early Trials
|
NRG1 overexpression
|
HER2 Positive Breast Cancer
|
NRG1 overexpression
|
HER2 Positive Breast Cancer
|
trastuzumab + pertuzumab Sensitive: C3 – Early Trials
|
trastuzumab + pertuzumab Sensitive: C3 – Early Trials
|
NRG1 overexpression
|
Head and Neck Cancer
|
NRG1 overexpression
|
Head and Neck Cancer
|
cetuximab Resistant: D – Preclinical
|
cetuximab Resistant: D – Preclinical
|